Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
Isolated, antigenic polypeptides including a pre-hairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Exemplary pre-hairpin intermediate conformations of gp41 include an oligomerization domain; a heptad repeat 2 motif; and a membrane-proximal external region, where the polypeptide lacks a heptad repeat 1 motif, and where the isolated, antigenic polypeptides elicit production of a broadly neutralizing antibody against HIV when injected into a subject. Antibodies that bind to a pre-hairpin intermediate conformation of gp41 and methods of making antibodies a that bind to pre-hairpin intermediate conformation of gp41 are also provided. Vaccines against a pre-hairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, pre-hairpin intermediate conformation of gp41 are further provided.
1. An isolated, antigenic polypeptide comprising a pre-hairpin intermediate conformation of gp41 including:
an oligomerization domain;
a heptad repeat 2 motif; and
a membrane-proximal external region,
wherein the polypeptide lacks a heptad repeat 1 motif, and wherein the polypeptide elicits production of a broadly neutralizing antibody against HIV when injected into a subject.
2. The polypeptide of claim 1 , further comprising a C-C loop domain.
3. The polypeptide of claim 1 , wherein the oligomerization domain is a coiled coil domain.
4. The polypeptide of claim 1 , wherein the polypeptide substantially fails to elicit production of weak or non-neutralizing antibodies when injected into a subject.
5. The polypeptide of claim 4 , wherein the weak or non-neutralizing antibodies are cluster II antibodies.
6. An isolated, antigenic polypeptide comprising a pre-hairpin intermediate conformation of gp41 including:
an oligomerization domain;
a heptad repeat 2 motif; and
a membrane-proximal external region,
wherein the polypeptide elicits production of a broadly neutralizing antibody and substantially fails to elicit production of cluster II antibodies against HIV when injected into a subject.
7. An isolated, antigenic polypeptide comprising a pre-hairpin intermediate conformation of gp41 including:
an oligomerization domain;
a heptad repeat 2 motif; and
a membrane-proximal external region,
wherein the polypeptide lacks a post-fusion conformation of gp41 comprising a heptad repeat 1 motif and a heptad repeat 2 motif arranged as a bundle, and wherein the polypeptide elicits production of a broadly neutralizing antibody against HIV when injected into a subject.
8. An isolated, antigenic polypeptide comprising a pre-hairpin intermediate conformation of gp41 in the following order:
an oligomerization domain at the amino terminus of the polypeptide;
a C-C loop domain carboxy terminal to the oligomerization domain;
a heptad repeat 2 motif carboxy terminal to the C-C loop; and
a membrane-proximal external region at the carboxy terminus of the polypeptide.
9. The polypeptide of claim 8 , wherein the polypeptide substantially fails to elicit production of weak or non-neutralizing antibodies when injected into a subject.
10. The polypeptide of claim 9 , wherein the weak or non-neutralizing antibodies are cluster II antibodies.
11. The polypeptide of claim 8 , wherein the polypeptide elicits production of a broadly neutralizing antibody when injected into a subject.
12. A method of inducing a neutralizing antibody response in a subject infected with a human immunodeficiency virus (HIV) comprising:
comprising administering to a subject infected with HIV an immunogenic composition comprising an isolated polypeptide comprising a pre-hairpin intermediate conformation of gp41 including an oligomerization domain, a heptad repeat 2 motif, and a membrane-proximal external region, and lacking a heptad repeat 1 domain;
wherein said polypeptide is capable of inducing a neutralizing antibody response against the HIV.
13. The method of claim 12 , wherein gp41 is expressed in a single conformation in the subject.
14. The method of claim 12 , wherein the polypeptide substantially fails to elicit production of cluster II antibodies in the subject.
15. A method of inhibiting HIV replication in a subject in need thereof comprising:
administering to an HIV-infected subject an immunogenic composition comprising an isolated polypeptide comprising a pre-hairpin intermediate conformation of an envelope glycoprotein including an oligomerization domain, a heptad repeat 2 motif, and a membrane-proximal external region, and lacking a heptad repeat 1 motif; and
inhibiting HIV replication.
16. The method of claim 15 , wherein the HIV-mediated activity is viral spread.
17. The method of claim 15 , wherein HIV titer in the HIV-infected subject is decreased.
18. A method of screening a compound that binds to an isolated, pre-hairpin intermediate conformation of gp41 comprising:
providing an isolated polypeptide including an oligomerization domain, a heptad repeat 2 motif, and a membrane-proximal external region, and lacking a heptad repeat 1 motif;
contacting the polypeptide with the compound; and
determining the ability of the compound to bind to the polypeptide, as compared to one or more controls.
19. A composition having an antigenic polypeptide comprising an isolated, pre-hairpin intermediate conformation of gp41 including an oligomerization domain, a heptad repeat 2 motif, and a membrane-proximal external region, and lacking a heptad repeat 1 motif, wherein the composition elicits production of a broadly neutralizing antibody against HIV when injected into a subject.
20. The method of claim 1 , wherein the oligomerization domain is a GCN4 trimerization domain.